10 June 2021
Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment of CNS Disorders
3 May 2021
Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinsonâ€™s Disease & Related Î±-synucleopathies at the XXVI IAPRD World Congress
18 March 2021
Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock
4 February 2021
Gain Therapeutics Announces Three Late-Breaker Presentations at the 17th Annual WORLDSymposium
10 September 2020
Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gainâ€™s Lysosomal Enzyme Allosteric Regulator Program
21 July 2020
Financing intended to accelerate IND-enabling studies of allosteric drug candidates for rare genetic and neurodegenerative diseases, expand pipeline and support business development activities
19 February 2019
Luxembourg, February 19, 2019: Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of high unmet patient need, today announces that it has made a â‚¬1 Million investment in Gain Therapeutics SA.
Thank you for your form submission, we will get in contact with you shortly.